Alnylam Suspends Fitusiran Dosing due to Thrombotic Event

Share on facebook
Share on google
Share on twitter
Share on linkedin
The Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.

VIA The Hemophilia Federation of America:

Alnylam recently became aware of a fatal serious adverse event (SAE) that occurred in a patient with hemophilia A who was receiving fitusiran in the Phase 2 OLE study. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.

Click here for Alnylam’s full press release link is: Press Release

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn

Leave a Reply

About Us

The Hemophilia Foundation of Michigan strives to improve the quality of life for all people affected by hemophilia, von Willebrand disease, other coagulation disorders, and related complications.

Recent Posts

It’s a Great Time to Review Your Insurance Plan for 2019

A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …

Read More →

What is an Accumulator Adjustment Program?

Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients using these cards.

Read More →

Follow Us

Sign up for our Newsletter

Get all the latest updates and news from  HFM